U.S. markets close in 4 hours 58 minutes
  • S&P 500

    4,587.74
    +36.06 (+0.79%)
     
  • Dow 30

    35,689.66
    +198.97 (+0.56%)
     
  • Nasdaq

    15,384.15
    +148.31 (+0.97%)
     
  • Russell 2000

    2,285.97
    +33.48 (+1.49%)
     
  • Crude Oil

    82.47
    -0.19 (-0.23%)
     
  • Gold

    1,800.70
    +1.90 (+0.11%)
     
  • Silver

    24.17
    -0.02 (-0.07%)
     
  • EUR/USD

    1.1681
    +0.0075 (+0.64%)
     
  • 10-Yr Bond

    1.5570
    +0.0280 (+1.83%)
     
  • GBP/USD

    1.3799
    +0.0057 (+0.41%)
     
  • USD/JPY

    113.3820
    -0.4280 (-0.38%)
     
  • BTC-USD

    61,522.67
    +2,243.09 (+3.78%)
     
  • CMC Crypto 200

    1,483.40
    +64.02 (+4.51%)
     
  • FTSE 100

    7,250.24
    -3.03 (-0.04%)
     
  • Nikkei 225

    28,820.09
    -278.15 (-0.96%)
     

RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 2021 Cantor Virtual Healthcare Conference on Monday, September 27, 2021 at 2:00 p.m. EST.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com